Aileron Therapeutics to Present at the 8th Annual IPF Summit

Company Overview - Aileron Therapeutics is a biopharmaceutical company focused on developing first-in-class medicines for significant unmet medical needs in orphan pulmonary and fibrosis indications [2] - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in a Phase 1b clinical trial for idiopathic pulmonary fibrosis [2] - Aileron's second product candidate, LTI-01, has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions and has received Orphan Drug Designation in the US and EU, as well as Fast Track Designation in the US [2] Upcoming Events - Brian Windsor, Ph.D., President and CEO of Aileron, will present at the 8th Annual IPF Summit on August 21, 2024, discussing biomarker strategies in the clinical development of LTI-03 [1] - The IPF Summit is a major drug development initiative for the pulmonary fibrosis community, featuring participation from key biopharmaceutical companies, clinicians, and academic researchers [1]